Ajanta Pharma Ltd

{"amount":28}

{"actualRevenue":14216400000,"estimateRevenue":13618000000,"revenueSurprise":598400000,"revenueSurprisePercent":4.394184168012924,"actualEPS":21.35,"estimateEPS":21.267,"surprise":0.08299999999999841,"surprisePercent":0.3902760144825241}

{"actualRevenue":13748400000,"estimateRevenue":13301000000,"revenueSurprise":447400000,"revenueSurprisePercent":3.363656867904669,"actualEPS":21.91,"estimateEPS":20.3319966,"surprise":1.578003399999997,"surprisePercent":7.761182686800155}

{"description":"Ajanta Pharma touched a record high after strong Q1 results and announced a 1,250% dividend payout, signaling robust performance and shareholder returns.","url":"https://www.zeebiz.com/markets/stocks/news-ajanta-pharma-share-price-nse-bse-sensex-nifty-q1-numbers-june-quarter-results-pharma-major-246486","sentiment":"Positive","domain":"Zee Business"}

{"description":"Ajanta Pharma reported Q4 net profit of ₹266.7 crore, up 18.4% YoY, on 21.5% revenue growth to ₹1,421.6 crore. FY26 profit rose 15% to ₹1,056 crore despite forex losses.","url":"https://www.cnbctv18.com/market/stocks/ajanta-pharma-share-price-q4-net-profit-rises-18-despite-rs-42-crore-forex-loss-revenue-grows-21-ws-l-19899140.htm","sentiment":"Positive","domain":"cnbctv18"}

{"description":"Ajanta Pharma reported a 17.6% rise in net profit to ₹274 crore and a 20% revenue increase to ₹1,375 crore for Q3 FY2026, driven by strong growth in its India branded generics business. The company's EBITDA also rose by 19.2%.","url":"https://www.cnbctv18.com/market/stocks/ajanta-pharma-share-price-posts-double-digit-q3-growth-on-20-revenue-rise-19837107.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Ajanta Pharma shares rose 13% over three months, with Motilal Oswal projecting a 16% upside and a target price of Rs 3,145. The company is focusing on chronic indications and expects significant revenue growth from new opportunities in Asia and Africa.","url":"https://www.goodreturns.in/news/ajanta-pharma-share-price-up-13-in-3-months-motilal-oswal-sees-16-upside-time-to-buy-check-targ-1478764.html","sentiment":"Positive","domain":"Goodreturns"}

{"description":"Ajanta Pharma, in partnership with Biocon, aims to tap into the growing weight-loss drug market, targeting a potential $100 billion market by 2030. They will market Semaglutide across 26 countries, starting product filings in FY28, with plans for a generic launch in India post-2026 patent expiry.","url":"https://www.cnbctv18.com/business/companies/ajanta-pharma-md-yogesh-agarwal-on-biocon-tie-up-for-weight-loss-drug-semaglutide-alpha-article-19801523.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Ajanta Pharma confirmed an ongoing Income Tax search at its offices and units, stating it is cooperating fully with officials and providing necessary clarifications.","url":"https://www.cnbctv18.com/market/stocks/ajanta-pharma-share-price-says-income-tax-search-ongoing-at-offices-units-19656879.htm","sentiment":"Negative","domain":"CNBCTV18"}